HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Summary

This is a first-in-human Phase 1/2, multinational, multicenter, open-label study of HB-302/HB-301 alternating 2-vector therapy in participants with metastatic castration-resistant prostate cancer (mCRPC) comprising 2 phases: a Phase 1 Dose Escalation and recommended Phase 2 dose (RP2D) Confirmation, and a Phase 2 Dose Expansion.

Timeline

Start

2023-05-23

Primary completion

2024-04-29

Completion

2024-04-29

Outcome

Outcome not reported

Stopped: “Decision by the company to terminate the H-300-001 study early for non-safety related reasons.”

Drugs

Indications